Inotuzumab Ozogamicin - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Inotuzumab Ozogamicin

Brand Name:

Besponsa

Strength:

0.9 mg

HCPCS:

Not yet assigned

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Drug Antibody Conjugate

Minor Drug Class:

CD22

Oral (Y/N):

No

FDA Approval Year:

2017

FDA Discontinuation Year:

CMS Effective Date:

CMS Discontinuation Date:

Status:

In Use